Vision Impairment News and Research RSS Feed - Vision Impairment News and Research

Brunel University student produces animated short film on understanding visually impaired people

As almost any of the UK's two million visually impaired (VI) will tell you people with full sight often make incorrect assumptions about their capabilities. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]

Envision presents awards for work in low vision rehabilitation

Envision presents the Lifetime Achievement Award from time-to-time to researchers whose careers have been marked by outstanding, creative and important contributions to low vision research... [More]
Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Johns Hopkins Ophthalmology professor Bob Massof receives Helen Keller prize

Bob Massof, Ph.D., of the Wilmer Eye Institute at Johns Hopkins received the 2015 Helen Keller Prize for Vision Research on May 5... [More]
TSRI study provides new insight into preventing diseases that cause vision loss in adults

TSRI study provides new insight into preventing diseases that cause vision loss in adults

A new study from scientists at The Scripps Research Institute shows that nerve cells and blood vessels in the eye constantly "talk" to each other to maintain healthy blood flow and prevent disease. [More]
Ranibizumab drug reverses diabetes-related blindness

Ranibizumab drug reverses diabetes-related blindness

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. [More]
RPB co-sponsors major IOM study to promote eye health

RPB co-sponsors major IOM study to promote eye health

Research to Prevent Blindness, the leading nonprofit driver of research toward cures and treatments for all blinding disorders, is co-sponsoring a major Institute of Medicine study entitled "Public Health Approaches to Reduce Vision Impairment and Promote Eye Health." [More]
Tackling preventable blindness: a House of Commons reception review

Tackling preventable blindness: a House of Commons reception review

“Macular degeneration is not life threatening, but it is life changing,” these were the words of Michael Valenzia, of the Macular Society at the recent House of Commons Reception held by AMD Alliance International. [More]
Monash Vision Group moves a step closer to Bionic Eye clinical trials

Monash Vision Group moves a step closer to Bionic Eye clinical trials

The Monash Vision Groupmoves a step closer to clinical trials of its Bionic Eye, thanks to landmark donations from two respected business leaders. [More]
Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). [More]
Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham. [More]
VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. [More]
OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

OMRF scientist selected to receive EMD Serono's Grant for Multiple Sclerosis Innovation

An Oklahoma Medical Research Foundation scientist has been selected to receive one of only five Grants for Multiple Sclerosis Innovation awarded this year by the pharmaceutical company EMD Serono. [More]

Bionic Vision Australia reports positive results of prototype implant in patients with RP-induced vision loss

Bionic Vision Australia (BVA), a consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss, today announced the successful completion of the first clinical trial of its prototype 24-channel percutaneous implant in patients with profound vision loss from the eye disease retinitis pigmentosa (RP). [More]
Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. [More]
Lifestyle factors modify vision impairment risk

Lifestyle factors modify vision impairment risk

Smoking, drinking alcohol and physical activity are modifiable behaviours that influence the risk of vision impairment, show findings from the Beaver Dam Eye Study. [More]
Research: New ways to help visually impaired better navigate everyday life

Research: New ways to help visually impaired better navigate everyday life

Visual impairment comes in many forms, and it's on the rise in America. A University of Cincinnati experiment aimed at this diverse and growing population could spark development of advanced tools to help all the aging baby boomers, injured veterans, diabetics and white-cane-wielding pedestrians navigate the blurred edges of everyday life. [More]

Digital reading system opens up new educational opportunities for people with vision impairment

People who are blind can now read more than just words, such as graphs and graphics, following the development of an affordable digital reading system by Curtin University researchers. [More]
Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. [More]
Shire intends to submit NDA for lifitegrast to treat dry eye disease

Shire intends to submit NDA for lifitegrast to treat dry eye disease

Following a May 15, 2014, meeting with the U.S. Food and Drug Administration (FDA), Shire plc, the global specialty biopharmaceutical company, announces today that it intends to submit a New Drug Application for lifitegrast as a treatment for the signs and symptoms of dry eye disease in adults in the first-quarter 2015, as we complete remaining chemistry and manufacturing work. [More]
Advertisement
Advertisement